What belongs in the full bill?

Keep the types of price separate.

As of September 2026, the medicine’s list price, cash price, and amount paid with insurance can differ.

The maker publishes a figure called the list price; what a person pays may be different.

Cash means paying for the medicine without using insurance.

These drug-maker cash offers cover approved medicines for diabetes or weight management. The examples are Wegovy and Ozempic (semaglutide), Zepbound and Mounjaro (tirzepatide), and Foundayo (orforglipron). As of September 2026, these offers mostly ran about $149–$499 a month.

The product, its strength, refill timing, and offer terms affect that figure; some refills cost more.

An offer priced “per month” may include a box, a bottle, or a 28-day supply, depending on the medicine. Ask how much medicine the price includes and how long it should last.

These are examples for the named medicines, not a price for every peptide treatment. Ask for a quote naming your medicine and whether it comes as pills, shots, or another type of product.

As of September 2026, five of six large national online weight-loss services checked advertised a monthly membership, with medicine charged separately.

Ask whether your service charges both fees. These examples do not tell you what your service charges.

Name each part of the bill.

Use these questions to compare complete plans. Keep the written answers with the quote.

• Visit or membership: is it paid once or billed again?
• Medicine: is it included, and what changes after an offer ends?
• Tests: which tests are proposed, and who bills for them?
• Follow-up: is a later review included?
• Stopping: how do I end the plan, and what can be refunded?

A Medicare example has narrow terms.

Medicare’s temporary weight-loss medicine program is called the Medicare GLP-1 Bridge. Here, GLP-1 names a group of diabetes and weight-loss medicines.

As of September 2026, it includes Wegovy (semaglutide) as shots or tablets, Foundayo (orforglipron) tablets, and Zepbound (tirzepatide) in its KwikPen injection device. Other Zepbound vials and pens are excluded.

As of September 2026, eligible people pay $50 a month as their copay: their share of the bill.

The federal Medicare agency lists a start date of July 1, 2026. It lists an end date of December 31, 2027.

Access needs a prescription and prior authorization: approval of a request before the medicine is covered.

Part D is Medicare’s prescription drug benefit.

The program has age, weight, health, and drug-plan requirements. People with type 2 diabetes use Medicare’s usual drug coverage instead, so they do not qualify for the Bridge.

As of September 2026, each $50 Bridge payment is extra spending that does not help you reach Part D’s yearly spending limit. Twelve monthly payments would cost $600 on top of what you pay for your other covered medicines.

Ask the prescriber to check the program’s full eligibility rules.

Ask what reason for treatment the plan covers.

As of September 2026, Medicare Part D excludes medicines used only for weight loss from its basic drug benefit.

Part D may cover the medicine for another accepted health problem, such as type 2 diabetes or reducing heart risk. Your plan must still include the drug on its list and approve your request if required.

Ask your plan: “Will you pay for this exact medicine for my health problem, what approval do you need, and what will I pay?”